Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
JACC. Cardiovascular Interventions|February 19, 2018
"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes StudyClemens von Birgelen, Marlies M Kok, Naveed Sattar, et al.
American Heart Journal|September 4, 2020
New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trialsEline H Ploumen, Rosaly A Buiten, Carine J M Doggen, et al.
Journal of the American Heart Association|November 8, 2022
Final 5-Year Report of the Randomized BIO-RESORT Trial Comparing 3 Contemporary Drug-Eluting Stents in All-ComersEline H Ploumen, Tineke H Pinxterhuis, Rosaly A Buiten, et al.
JACC. Cardiovascular Interventions|March 10, 2018
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) TrialPaolo Zocca, Marlies M Kok, Kenneth Tandjung, et al.
Lancet (London, England)|November 4, 2016
Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trialClemens von Birgelen, Marlies M Kok, Liefke C van der Heijden, et al.
JACC. Cardiovascular Interventions|May 25, 2015
Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II)Hanim Sen, Ming Kai Lam, Marije M Löwik, et al.
Lancet (London, England)|November 5, 2013
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trialClemens von Birgelen, Hanim Sen, Ming Kai Lam, et al.
Pageof 6